Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary

Abstract

The pandemic of COVID-19 (Coronavirus Disease-2019) is an extremely contagious respiratory illness due to a novel coronavirus, SARS-CoV-2. Certain drugs have several protein targets and many illnesses share overlapping molecular paths. In such cases, reusing drugs for more than one objective and finding their novice uses can considerably decrease the time in finding new cures for unforeseen diseases. Remdesivir has been recently a strong candidate for the treatment of Covid-19. In this commentary, we have portrayed the structure of the coronavirus in a simple way as well as the site where remdesivir acts. We have also displayed the ongoing clinical trials, as well as a published study that was conducted on compassionate base. The covid-19 pandemic might wean down by the end of summer 2020, but the risk of seasonality exists. Therefore, future disposal of agents such as remdesivir might be crucial for ensuring an efficient treatment, decrease mortality and allow early discharge. ARTICLE HISTORY

In silico investigation of phytoconstituents from Indian medicinal herb ‘Tinospora cordifolia(giloy)’ against SARS-CoV-2 (COVID-19) by molecular dynamics approach

“…The proteins (S) which are associated with replication, are the primary targets of post-entry treatment drugs or vaccine design which can suppress viral replication/infection or neutralizing antibodies (Abs) upon infection (Gao et al, 2020;Gupta et al, 2020;Khan, Zia, et al, 2020;Sarma et al, 2020). SARS-CoV-2 3C like proteinase is already predicted to bind with different FDA approved antiviral commercially available drugs like atazanavir, lopinavir, ritonavir, remdesivir, efavirenz and some other antiviral drugs which have a predicted affinity with clear efficacy value of K d > 100 nM potency (Hendaus, 2020;Khan, Jha, et al, 2020). Prediction suggests that viral proteinase targeting drugs should act very efficiently on the viral replication process.…”

“…Also some conventional FDA approved drugs (Remdesivir, Nelfinavir, Paritaprevir, Raltegravir, Praziquantel, etc. ) are being tried as the potential drug against this CoV-2 and found with certain curative effect in vitro (Hendaus, 2020;Khan, Jha, et al, 2020;Wang, Cao, et al, 2020). But till no none of the clinically applied drug/vaccine response is found to be very encouraging.…”

Natural compounds as potential inhibitors of novel coronavirus (COVID-19) main protease: An in silico study

“…Coronavirus disease (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which primarily affects the lungs and shows certain types of pneumonia-like symptoms (Huang et al, 2020;Kumar et al, 2020). SARS-CoV-2 is a novel strain of coronavirus, rst time emerged in December 2019, during an outbreak in Wuhan, China, and subsequently expanded to all over the world in a very short period of time (World Health Organization, 2020; Hendaus, 2020). The outbreak was declared a Public Health Emergency of International Concern by WHO on 30 January 2020 (WHO, 2020).…”

A case report: remdesivir effective in the treatment of severe category COVID-19

“…In addition, it has shown to have a wide therapeutic index in a human airway epithelial cell model The drug also exhibits a high genetic hurdle to resistance in coronaviruses and has an extended intracellular halflife that permits for once-daily dosing. [5][6][7] We had reviewed the literature with great interest for the successful application of remdesivir to cure a COVID-19 patient, and clinical trials indicate that this drug may have significant potential as an antiviral, and thus we report our case as an experience with remdesivir.…”